|
News Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
Genzyme, a Sanofi company, reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif®), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS). |
|
News Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
Genzyme Corp., a subsidiary of sanofi-aventis Group, reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug. |
|
News Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Genzyme, a subsidiary of sanofi-aventis Group, announced that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology`s (AAN) 63rd Annual Meeting in Hawaii. |
|
Leaflet Drug Rebif
Description: Interferon beta-1a is used to treat the relapsing forms of multiple sclerosis (MS). |
|
Leaflet Drug Interferon Beta-1a (Intramuscular Route, Subcutaneous Route, Injection Route)
Description: Interferon beta-1a is used to treat the relapsing forms of multiple sclerosis (MS). |
|
Leaflet Drug Avonex
Description: Interferon beta-1a is used to treat the relapsing forms of multiple sclerosis (MS). |
